Skip to main content

February 2017

Volume 29 Issue 2
We present a case of double-lumen formation seen at 1 year post CTO-PCI using subintimal dissection reentry with late restoration of major side branches.
We present a highly anomalous coronary anatomy, where coronary angiography revealed a non-dominant right coronary artery and a long anomalous branch of the proximal left anterior descending coronary artery that coursed inferiorly to give rise to the…
We report a case with the first use of dedicated software for fluoroscopic simulation (FluoroCT) in transcatheter mitral paravalvular leak closure.
This case demonstrates a potential role of transcatheter mitral valve repair in treating acute severe mitral regurgitation due to endocarditis.
The SoundBite Crossing System (SoundBite Medical Solutions, Inc) is a newly-developed device using shockwaves (short-duration, high-amplitude pressure pulses) delivered to the tip of guidewire to facilitate penetration of the proximal cap and crossin…
We compared transcatheter aortic valve implantation outcomes of the Evolut-R and CoreValve devices. This study indicates that the efficacy and safety of the self-expandable second-generation Evolut-R transcatheter valve is at least comparable with th…
We analyzed the incidence of bradycardia and the safety of patients with severely calcified coronary lesions who underwent orbital atherectomy without the insertion of a temporary pacemaker.
Identifying the presence of double inferior vena cava is important in order to define its relationship with the renal vein, its size when IVC filters are planned, the location of the left renal vein in relationship to the aorta, and for planning of I…
We tested the ability of the SYNTAX score to predict 1-year adverse outcomes for patients with non–ST segment elevation acute coronary syndromes who undergo coronary artery bypass graft surgery.
Synergy stents (Boston Scientific) allow for early cessation of DAPT. This study assessed those in our unit who underwent PCI with a Synergy stent to examine a minimum of 6 months of clinical outcomes after early discontinuation of DAPT.
Back to Top